Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Interest Expenses (2016 - 2017)

Historic Interest Expenses for Capricor Therapeutics (CAPR) over the last 9 years, with Q4 2017 value amounting to $80307.0.

  • Capricor Therapeutics' Interest Expenses fell 2196.01% to $80307.0 in Q4 2017 from the same period last year, while for Sep 2018 it was $80307.0, marking a year-over-year decrease of 8094.3%. This contributed to the annual value of $398807.0 for FY2017, which is 1570.86% up from last year.
  • Latest data reveals that Capricor Therapeutics reported Interest Expenses of $80307.0 as of Q4 2017, which was down 2196.01% from $107653.0 recorded in Q3 2017.
  • In the past 5 years, Capricor Therapeutics' Interest Expenses registered a high of $107653.0 during Q3 2017, and its lowest value of $3711.0 during Q1 2013.
  • For the 5-year period, Capricor Therapeutics' Interest Expenses averaged around $64519.9, with its median value being $61681.0 (2015).
  • In the last 5 years, Capricor Therapeutics' Interest Expenses skyrocketed by 78075.99% in 2014 and then plummeted by 2196.01% in 2017.
  • Capricor Therapeutics' Interest Expenses (Quarter) stood at $23353.0 in 2013, then skyrocketed by 158.57% to $60383.0 in 2014, then grew by 5.3% to $63583.0 in 2015, then surged by 61.84% to $102905.0 in 2016, then dropped by 21.96% to $80307.0 in 2017.
  • Its Interest Expenses stands at $80307.0 for Q4 2017, versus $107653.0 for Q3 2017 and $105527.0 for Q2 2017.